Venetoclax 100 MG

DRUG2 trials

Sponsors

Virginia Commonwealth University, Hospital Universitario Dr. Jose E. Gonzalez

Conditions

AMLRefractory Small Cell Lung CarcinomaRelapsed Small Cell Lung Cancer

Phase 1

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

WithdrawnNCT04543916

Virginia Commonwealth UniversityRefractory Small Cell Lung Carcinoma, Relapsed Small Cell Lung Cancer

Start: 2021-06-30End: 2028-06-30Updated: 2021-03-03

Phase 2

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

CompletedNCT05048615

Hospital Universitario Dr. Jose E. GonzalezAML

Start: 2021-07-26End: 2023-01-20Updated: 2023-01-25

Related Papers

Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting

Blood2023-11-023 citations

Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study

Leukemia Research2023-08-228 citations